Abstract
Early pregnancy loss is a common complication of pregnancy. Research has demonstrated the efficacy of Mifepristone pre-treatment followed by Misoprostol for the induction of an early pregnancy loss (EPL). North York General Hospital (NYGH) provides an all-in-one Early Pregnancy Assessment Clinic (EPAC) to streamline the care of women with an EPL. We conducted a prospective single cohort qualitative survey to understand patients' satisfaction with the Mifepristone and Misoprostol and their experience with EPAC at NYGH. We recruited 191 patients with a confirmed EPL. They were given Mifepristone and Misoprostol. We administered the validated modified version of the Short Form-36 Health Survey Revised (SF-36R) QOL scales questionnaire to study the following outcomes: (1) Acceptability of Mifepristone and Misoprostol: cramping, bleeding, duration of treatment, and recommendation to others; (2) Effect on Social Activities; and (3) Participants' overall satisfaction with the EPAC at NYGH. We found that 96% of our participants responded completely to our questionnaire. For cramping, 24% reported definitely acceptable, while 8% reported definitely unacceptable. For bleeding, 26% reported definitely acceptable, while 4.8% reported definitely unacceptable. For the duration of treatment, 27% reported definitely acceptable and 2.7% reported definitely unacceptable. Finally, for recommendation to others, 41% reported definitely acceptable and 2.1% definitely unacceptable. The rating for NYGH's EPAC was high, where 68% of participants rated it excellent. We found that the acceptability of the medical management at our EPAC for an EPL is high with the Mifepristone and Misoprostol protocol. This study encourages this treatment and establishment of similar centers.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call